Daniel Ventura

Summary

Affiliation: Forest Research Institute
Country: USA

Publications

  1. ncbi Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial
    Daniel Ventura
    Forest Research Institute, Jersey City, NJ 07311, USA
    Curr Med Res Opin 23:245-50. 2007
  2. ncbi Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil
    Antonia P Periclou
    Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Jersey City, NJ 07311 4994, USA
    Ann Pharmacother 38:1389-94. 2004
  3. ncbi Pharmacokinetic study of memantine in healthy and renally impaired subjects
    Antonia Periclou
    Forest Research Institute, Jersey City, NJ, USA
    Clin Pharmacol Ther 79:134-43. 2006
  4. ncbi Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study
    Niranjan Rao
    Forest Research Institute, Forest Laboratories, Inc, Jersey City, New Jersey, USA
    Clin Ther 27:1596-606. 2005
  5. ncbi A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder
    Robert J Bielski
    Summit Research Network, Okemos, MI 48864, USA
    J Clin Psychiatry 65:1190-6. 2004
  6. ncbi A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression
    Karen Dineen Wagner
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston 77555 0144, USA
    J Am Acad Child Adolesc Psychiatry 45:280-8. 2006

Detail Information

Publications6

  1. ncbi Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial
    Daniel Ventura
    Forest Research Institute, Jersey City, NJ 07311, USA
    Curr Med Res Opin 23:245-50. 2007
    ..This trial was conducted to compare the efficacy and tolerability of a fixed dose of escitalopram 10 mg/day with sertraline optimally dosed within its recommended dose range (50-200 mg/day) for the treatment of major depressive disorder...
  2. ncbi Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil
    Antonia P Periclou
    Clinical Pharmacology and Drug Dynamics, Forest Research Institute, Jersey City, NJ 07311 4994, USA
    Ann Pharmacother 38:1389-94. 2004
    ..Memantine, a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist, was approved in the US for treatment of moderate to severe Alzheimer's disease in October 2003...
  3. ncbi Pharmacokinetic study of memantine in healthy and renally impaired subjects
    Antonia Periclou
    Forest Research Institute, Jersey City, NJ, USA
    Clin Pharmacol Ther 79:134-43. 2006
    ..Our objective was to evaluate the pharmacokinetics of the Alzheimer's disease treatment memantine in subjects with normal and impaired renal function...
  4. ncbi Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study
    Niranjan Rao
    Forest Research Institute, Forest Laboratories, Inc, Jersey City, New Jersey, USA
    Clin Ther 27:1596-606. 2005
    ..Given the renal tubular transport and extensive urinary excretion of memantine and metformin, it was of interest to assess the pharmacokinetic and pharmacodynamic interaction with glyburide/metformin...
  5. ncbi A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder
    Robert J Bielski
    Summit Research Network, Okemos, MI 48864, USA
    J Clin Psychiatry 65:1190-6. 2004
    ..Venlafaxine is a non-selective SRI that also inhibits noradrenergic re-uptake. This study compared escitalopram and venlafaxine extended release (XR) in depressed outpatients at the highest doses recommended in the United States...
  6. ncbi A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression
    Karen Dineen Wagner
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston 77555 0144, USA
    J Am Acad Child Adolesc Psychiatry 45:280-8. 2006
    ..Escitalopram is a selective serotonin reuptake inhibitor antidepressant indicated for use in adults. This trial examined the efficacy and safety of escitalopram in pediatric depression...